Filter By Category
Archives
Share on -
ABIRATERONE
Generic Name: ABIRATERONE
ABSTRACT -
Abiraterone inhibits CYP17, reducing androgen production in the testes, adrenal glands, and prostate-tumour tissue. It is used with a corticosteroid in selected prostate-cancer settings.
DOSAGE –
Use the current locally approved prescribing information where a product is authorized. For investigational products, dose, route, schedule, premedication, and dose modifications must come only from the applicable clinical-trial protocol. No dose should be selected from this summary.
SIDE EFFECTS –
- Hypertension
- Low potassium
- Fluid retention or oedema
- Liver-enzyme elevation
- Fatigue
- Hot flushes or joint discomfort
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Hives or a rapidly spreading rash
- Swelling of the face, lips, tongue, or throat
- Wheezing, breathing difficulty, or sudden dizziness
- Severe blistering, mucosal lesions, or anaphylaxis
DRUG INTERACTIONS -
- CYP3A inducers may lower exposure
- Abiraterone can affect CYP2D6 substrates
- Medicines that lower potassium or prolong QT require review
PRECAUTIONS –
- Monitor blood pressure, potassium, fluid status, and liver function
- Use with the prescribed corticosteroid
- Review cardiovascular and adrenal history
WARNINGS –
- Mineralocorticoid excess, hepatotoxicity, and adrenal insufficiency can be serious
- Not for use during pregnancy
Share on -
. Developed by